


**Product Name** : Sonidegib  
**Cat. No.** : PC-38709  
**CAS No.** : 956697-53-3  
**Molecular Formula** : C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>  
**Molecular Weight** : 485.507  
**Target** : Smoothed (Smo)  
**Solubility** : 10 mM in DMSO



### Biological Activity

Sonidegib (Erismodegib, LDE225, NVP-LDE225) is potent, selective, orally available **Smoothed** (SMO) antagonist, inhibits Hedgehog (Hh) signaling with IC<sub>50</sub> of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. LDE225 treatment also increased sensitivity of ALDH-positive cells to paclitaxel in ovarian cancer. LDE225 decreased MM cell viability by inducing specific down-regulation of Gli1 and Ptch1, hallmarks of Hh activity. LDE225 showed antitumor efficacy in combination with bortezomib both in vitro and in vivo in multiple myeloma.

### References

- Pan S, et al. *ACS Med Chem Lett*. 2010 Mar 16;1(3):130-4.  
Buonamici S, et al. *Sci Transl Med*. 2010 Sep 29;2(51):51ra70.  
Heller E, et al. *Cancer Res*. 2012 Feb 15;72(4):897-907.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com